PTPN2 and melanoma: In order to dissect the mechanism by which PTPN2 acts as an oncogene in melanoma and how its loss correlates with increased sensitivity of tumor cells to immunotherapy, it is important to underline that the tyrosine phosphatase inhibits IFNγ signaling by dephosphorylating STAT1 and JAK1.